期刊
NUCLEIC ACIDS RESEARCH
卷 38, 期 4, 页码 1228-1239出版社
OXFORD UNIV PRESS
DOI: 10.1093/nar/gkp1102
关键词
-
资金
- Wellcome Trust [081977/Z/07/Z]
- Wellcome Trust PhD program Molecular Functions in Disease
- Cancer Research UK
- Wellcome Trust [081977/Z/07/Z] Funding Source: Wellcome Trust
Dr1 (also known as NC2 beta) was identified as a repressor of RNA polymerase (pol) II transcription. It was subsequently shown to inhibit pol III transcription when expressed at high levels in vitro or in yeast cells. However, endogenous Dr1 was not detected at pol III-transcribed genes in growing yeast. In contrast, we demonstrate that endogenous Dr1 is present at pol III templates in human cells, as is its dimerization partner DRAP1 (also called NC2 alpha). Expression of tRNA by pol III is selectively enhanced by RNAi-mediated depletion of endogenous human Dr1, but we found no evidence that DRAP1 influences pol III output in vivo. A stable association was detected between endogenous Dr1 and the pol III-specific transcription factor Brf1. This interaction may recruit Dr1 to pol III templates in vivo, as crosslinking to these sites increases following Brf1 induction. On the basis of these data, we conclude that the physiological functions of human Dr1 include regulation of pol III transcription.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据